Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients.
van Geel AN, Pastorino U, Jauch KW, Judson IR, van Coevorden F, Buesa JM, Nielsen OS, Boudinet A, Tursz T, Schmitz PI. van Geel AN, et al. Among authors: nielsen os. Cancer. 1996 Feb 15;77(4):675-82. doi: 10.1002/(sici)1097-0142(19960215)77:4<675::aid-cncr13>3.3.co;2-h. Cancer. 1996. PMID: 8616759
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, Steward W, Daugaard S, van Glabbeke M, Kirkpatrick A, Tursz T. Nielsen OS, et al. Br J Cancer. 1998 Dec;78(12):1634-9. doi: 10.1038/bjc.1998.735. Br J Cancer. 1998. PMID: 9862576 Free PMC article. Clinical Trial.
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS. Verweij J, et al. Among authors: nielsen os. Eur J Cancer. 2003 Sep;39(14):2006-11. Eur J Cancer. 2003. PMID: 12957454 Clinical Trial.
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, van Oosterom A, Radford JA, Svancárová L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW, Verweij J. Nielsen OS, et al. Eur J Cancer. 2000 Jan;36(1):61-7. doi: 10.1016/s0959-8049(99)00240-3. Eur J Cancer. 2000. PMID: 10741296 Clinical Trial.
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, Svancarova L, Spooner D, Hermans C, Van Glabbeke M, Verweij J; EORTC Soft Tissue and Bone Sarcoma Group. van Oosterom AT, et al. Among authors: nielsen os. Eur J Cancer. 2002 Dec;38(18):2397-406. doi: 10.1016/s0959-8049(02)00491-4. Eur J Cancer. 2002. PMID: 12460784 Clinical Trial.
165 results